Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial

Sophie G. Carter, Jayne C. Carberry, Garry Cho, Lauren P. Fisher, Charlotte M. Rollo, David J. Stevens, Angela L. D'Rozario, David K. McKenzie, Ronald R. Grunstein, Danny J. Eckert
European Respiratory Journal 2018 52: 1800149; DOI: 10.1183/13993003.00149-2018
Sophie G. Carter
1Neuroscience Research Australia (NeuRA), Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jayne C. Carberry
1Neuroscience Research Australia (NeuRA), Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garry Cho
2The Woolcock Institute of Medical Research, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren P. Fisher
1Neuroscience Research Australia (NeuRA), Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte M. Rollo
1Neuroscience Research Australia (NeuRA), Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Stevens
2The Woolcock Institute of Medical Research, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela L. D'Rozario
2The Woolcock Institute of Medical Research, Sydney, Australia
3School of Psychology, Faculty of Science, Brain and Mind Centre and Charles Perkins Centre, The University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David K. McKenzie
4Prince of Wales Hospital, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald R. Grunstein
2The Woolcock Institute of Medical Research, Sydney, Australia
5Royal Prince Alfred Hospital and Sydney Local Heath District, Camperdown, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danny J. Eckert
1Neuroscience Research Australia (NeuRA), Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    CONSORT flow diagram indicating the enrolment, randomisation, allocation, follow-up and analysis procedures for this double-blind, placebo-controlled, parallel trial. Initially, participants with a confirmed diagnosis or clinical suspicion of OSA responded to a research advertisement or were contacted via a research volunteer database. Participants attended an in-laboratory physiology screening PSG to determine eligibility for the trial. Eligible patients (untreated OSA (apnoea–hypopnoea index ≥5 events·h−1), overnight nadir SaO2 ≥75% and low–moderate respiratory arousal threshold (≥ −25 cmH2O) that were otherwise healthy) attended a standard in-laboratory baseline PSG. If still eligible following baseline, patients were then randomised to either the placebo or zopiclone condition. Participants received either once-nightly placebo or 7.5 mg of zopiclone just prior to bed for 1 month. Participants attended two standard in-laboratory PSGs on the first (night 1) and last night (night 30) of the treatment nights. One patient was excluded from the study after the baseline PSG as they were found not to have OSA. One patient discontinued involvement in the study prior to completing night 30 due to an unrelated personal issue. PSG: polysomnography; SaO2: arterial blood oxygen saturation; OSA: obstructive sleep apnoea; CPAP: continuous positive airway pressure.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Polysomnographic recordings in an individual patient demonstrating how the respiratory arousal threshold measures were obtained. This example shows an ∼40-s epoch of non-rapid eye movement N2 sleep in which the 35-year-old male patient (apnoea–hypopnoea index 20 events·h−1; body mass index 32.2 kg·m−2) experienced an ∼25-s respiratory event (shaded area of the respiratory flow channel labelled “Obstructive apnoea”) that ended with a cortical arousal from sleep (shaded area of the two EEG channels labelled “Arousal”). The respiratory arousal threshold is quantified as the nadir epiglottic pressure during the respiratory effort occurring immediately prior to arousal (circled area on the epiglottic pressure channel, in this example approximately −32 cmH2O). Flow is the nasal airflow measured via a mask and pneumotachograph; mask pressure is the pressure at the nasal mask measured using a pressure transducer. EEG: electroencephalogram.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    a) Apnoea–hypopnoea index (AHI) scatter plot representing each individual's AHI during placebo (n=16) versus zopiclone (n=14) conditions for baseline and night 30. Grey lines and error bars indicate mean±sd. *: significant difference from baseline. b) Scatter plot indicating each individual's change in AHI (ΔAHI) from baseline to night 30 for both conditions. Lines and error bars indicate mean±sd.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Participant anthropometric and sleep characteristics

    PlaceboZopiclone
    Participants1614
    Sex
     Male1312
     Female32
    Age years46±1350±8
    BMI kg·m−229±428±4
    Mean AHI events·h−121±1023±12
    AHI range events·h−16–386–53
    Arousal threshold cmH2O−16±5−16±7

    Data are presented as n or mean±sd, unless otherwise stated. Group anthropometric and baseline obstructive sleep apnoea severity data acquired from the baseline and physiology (for respiratory arousal threshold data only) overnight sleep studies. BMI: body mass index; AHI: apnoea–hypopnoea index.

    • TABLE 2

      Adverse events reported during the 1-month trial

      PlaceboZopiclone#Related to zopiclone¶
      MinorSeriousMinorSerious
      Abnormal dreams2/161/15Probably
      Abscess drainage1/15No
      Anxiety1/15Possibly
      Balance disorder1/15Probably
      Bradycardia1/16
      Change in sleep pattern3/16
      Constipation1/16
      Decreased appetite2/15Probably
      Diarrhoea1/15Probably
      Disturbance in memory or attention2/15Probably
      Dysgeusia3/15Definite
      Fatigue or asthenia1/161/15Probably
      Feeling abnormal2/15Probably
      Headache or migraine2/15Probably
      Insomnia2/15Possibly
      Joint swelling1/15No
      Loss of libido1/15Probably
      Muscle ache or injury1/161/15No
      Nasopharyngitis2/161/15No
      Oral ulcer1/16
      Rash2/16
      Stress1/15Possibly
      Weight loss2/15Possibly

      Data represent adverse events reported during the 1-month trial or during the week after completion. None of these events required withdrawal from the study. A total of seven out of 16 participants randomised to placebo and 14 out of 15 randomised to zopiclone reported adverse events during the 1-month trial. Six participants in the placebo group and eight in the zopiclone group reported more than one adverse event. #: one participant from the zopiclone group withdrew from the study prior to completing the 1-month trial due to nonmedical issues; ¶: whether each adverse event was related to zopiclone was determined by a physician according to the following criteria: not related (“No”), unlikely, possibly, probably or definitely.

      • TABLE 3

        Participant feedback at study conclusion

        PlaceboZopiclone
        Did you feel like your sleep improved or worsened?
         Improved9/1611/14
         Worsened1/161/14
         Same6/162/14
        If available, would you continue to use the study medication?
         Yes5/165/14
         No10/169/14
         Unsure1/160/14
        Do you feel like you were taking the sleeping pill or the placebo during the study?
         Placebo11/163/14
         Zopiclone5/1611/14

        Data are presented as counts according to participant feedback over the 1-month trial. Data were collected on the morning of the final visit (night 30).

        • TABLE 4

          Placebo and zopiclone polysomnography data for the 8-h overnight sleep studies during the baseline and night 30 conditions

          Placebo#Zopiclone¶Delta changep-value
          BaselineNight 30BaselineNight 30
          Sleep onset latency min10 (6–13)6 (2–15)9 (5–26)16 (10–32)6 (−11–17)0.47
          Sleep efficiency % sleep84±785±1079±1386±65 (−2–13)0.16
          TST min415±34424±45386±61427±2732 (−2–67)0.07
          Non-REM sleep N1 % TST7±45±310±37±4−1 (−3–1)0.35
          Non-REM sleep N2 % TST49±849±746±1049±74 (−3–10)0.24
          Non-REM sleep N3 % TST25±626±724±724±4−1 (−4–4)0.80
          REM sleep % TST19±520±520±519±5−2 (−6–2)0.33
          Wake after sleep onset min71±3365±5187±5653±32−28 (−61–6)0.10
          Arousal index arousals·h−127±1024±1128±1124±8−1 (−8–6)0.75
          Supine % TST48±2852±3149±2846±28−7 (−25–11)0.43
          Supine AHI events·h−138±2832±2146±2437±23−2 (−14–18)0.82
          Low arousal threshold AHI events·h−1+23±1220±1121±1116±10−1 (−10–8)0.82
          Moderate arousal threshold AHI events·h−1§19±718±1026±1419±5−6 (−16–3)0.18
          Respiratory event duration s25±327±527±527±5−2 (−6–1)0.20
          Mean SaO2 during sleep %95±295±194±294±20 (−1–1)0.93
          Nadir SaO2 during sleep %86±586±686±685±5−1 (−4–3)0.64

          Data are presented as mean±sd or median (interquartile range), unless otherwise stated; the delta change column indicates the difference from baseline to night 30 between conditions (mean (95% CI) for normally distributed data and Hodge–Lehmann estimated median (95% CI) for nonnormally distributed data). REM: rapid eye movement; TST: total sleep time; AHI: apnoea–hypopnoea index; SaO2: estimated arterial blood oxygen saturation (measured via pulse oximetry). #: n=16; ¶: n=14; +: for low arousal threshold (> −15 cmH2O) AHI, n=9 in the placebo group and n=7 in the zopiclone group; §: for moderate arousal threshold (< −15 and > −25 cmH2O) AHI, n=7 in the placebo and zopiclone groups. p-values refer to the difference from baseline to night 30 compared between placebo and zopiclone conditions.

          • TABLE 5

            Placebo and zopiclone sleepiness/alertness and driving simulator performance data collected during the baseline and night 30 conditions

            Placebo#Zopiclone¶Delta changep-value
            BaselineNight 30BaselineNight 30
            ESS+5 (4–12)6 (4–11)8 (5–12)7 (4–9)−1 (−4–1)0.55
            FOSQ+101±11101±12101±8103±113 (−2–7)0.25
            Leeds§5±15±14±15±10 (−1–1)0.62
            KSS6±26±26±16±20 (−1–1)>0.99
            AusEd driving simulator
             Deviation from median of lane cm59±2251±1348±1647±137 (−1–15)0.10
             Deviation from 60–80 km·h−1 km·h−12±22±12±12±11 (0–1)0.11
             Braking reaction time ms+1016±2331017±2031034±312957±206−77 (−206–50)0.22

            Data are presented as mean±sd or median (interquartile range), unless otherwise stated; the delta change column indicates the difference from baseline to night 30 between conditions (mean (95% CI) for normally distributed data and Hodge–Lehmann estimated median (95% CI) for nonnormally distributed data). Epworth Sleepiness Scale (ESS) and Functional Outcomes of Sleep Questionnaire (FOSQ) data were collected in the evening 1.5 h prior to sleep; Leeds Sleep Evaluation Questionnaire (Leeds), Karolinska Sleepiness Scale (KSS) and AusEd data were collected 30 min after awakening. #: n=16; ¶: n=14; +: for ESS, FOSQ and AusEd braking reaction time n=15 in the placebo group; §: for Leeds n=13 in the placebo group and n=11 in the zopiclone group. p-values refer to the difference from baseline to night 30 compared between placebo and zopiclone conditions.

            Supplementary Materials

            • Figures
            • Tables
            • Supplementary Material

              Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

              Supplementary material ERJ-00149-2018_Supplement

            PreviousNext
            Back to top
            View this article with LENS
            Vol 52 Issue 1 Table of Contents
            European Respiratory Journal: 52 (1)
            • Table of Contents
            • Index by author
            Email

            Thank you for your interest in spreading the word on European Respiratory Society .

            NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

            Enter multiple addresses on separate lines or separate them with commas.
            Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial
            (Your Name) has sent you a message from European Respiratory Society
            (Your Name) thought you would like to see the European Respiratory Society web site.
            CAPTCHA
            This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
            Print
            Alerts
            Sign In to Email Alerts with your Email Address
            Citation Tools
            Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial
            Sophie G. Carter, Jayne C. Carberry, Garry Cho, Lauren P. Fisher, Charlotte M. Rollo, David J. Stevens, Angela L. D'Rozario, David K. McKenzie, Ronald R. Grunstein, Danny J. Eckert
            European Respiratory Journal Jul 2018, 52 (1) 1800149; DOI: 10.1183/13993003.00149-2018

            Citation Manager Formats

            • BibTeX
            • Bookends
            • EasyBib
            • EndNote (tagged)
            • EndNote 8 (xml)
            • Medlars
            • Mendeley
            • Papers
            • RefWorks Tagged
            • Ref Manager
            • RIS
            • Zotero

            Share
            Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial
            Sophie G. Carter, Jayne C. Carberry, Garry Cho, Lauren P. Fisher, Charlotte M. Rollo, David J. Stevens, Angela L. D'Rozario, David K. McKenzie, Ronald R. Grunstein, Danny J. Eckert
            European Respiratory Journal Jul 2018, 52 (1) 1800149; DOI: 10.1183/13993003.00149-2018
            del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
            Full Text (PDF)

            Jump To

            • Article
              • Abstract
              • Abstract
              • Introduction
              • Methods
              • Results
              • Discussion
              • Supplementary material
              • Acknowledgements
              • Footnotes
              • References
            • Figures & Data
            • Info & Metrics
            • PDF

            Subjects

            • Sleep medicine
            • Tweet Widget
            • Facebook Like
            • Google Plus One

            More in this TOC Section

            Original articles

            • EmPHasis-10 as a measure of quality of life in PAH
            • EmPHasis-10 health-related quality of life score predicts outcomes in PAH
            • Periostin and airway epithelial function in asthma
            Show more Original articles

            Sleep

            • Desaturations increase PVT-based reaction time in OSA
            • Suboptimal adherence to CPAP therapy in OSA
            • CPAP treatment in elderly patients with moderate OSA
            Show more Sleep

            Related Articles

            Navigate

            • Home
            • Current issue
            • Archive

            About the ERJ

            • Journal information
            • Editorial board
            • Reviewers
            • CME
            • Press
            • Permissions and reprints
            • Advertising

            The European Respiratory Society

            • Society home
            • myERS
            • Privacy policy
            • Accessibility

            ERS publications

            • European Respiratory Journal
            • ERJ Open Research
            • European Respiratory Review
            • Breathe
            • ERS books online
            • ERS Bookshop

            Help

            • Feedback

            For authors

            • Instructions for authors
            • Submit a manuscript
            • ERS author centre

            For readers

            • Alerts
            • Subjects
            • Podcasts
            • RSS

            Subscriptions

            • Accessing the ERS publications

            Contact us

            European Respiratory Society
            442 Glossop Road
            Sheffield S10 2PX
            United Kingdom
            Tel: +44 114 2672860
            Email: journals@ersnet.org

            ISSN

            Print ISSN:  0903-1936
            Online ISSN: 1399-3003

            Copyright © 2021 by the European Respiratory Society